XML 41 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill And Other Intangibles (Tables)
 9 Months Ended
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amount of our goodwill for the nine months ended September 30, 2017 were as follows (in thousands):
 
Carrying Amount
 
U.S. Generic Pharmaceuticals
 
U.S. Branded Pharmaceuticals
 
International Pharmaceuticals
 
Total
Goodwill as of December 31, 2016
$
3,531,301

 
$
1,009,248

 
$
188,846

 
$
4,729,395

Effect of currency translation on gross balance
—

 
—

 
47,477

 
47,477

Effect of currency translation on accumulated impairment
—

 
—

 
(37,330
)
 
(37,330
)
Goodwill impairment charges
—

 
(180,430
)
 
(108,314
)
 
(288,744
)
Goodwill as of September 30, 2017
$
3,531,301

 
$
828,818

 
$
90,679

 
$
4,450,798


The carrying amounts of goodwill at September 30, 2017 and December 31, 2016 are net of the following accumulated impairments:
 
Accumulated Impairment
 
U.S. Generic Pharmaceuticals
 
U.S. Branded Pharmaceuticals
 
International Pharmaceuticals
 
Total
Accumulated impairment losses as of December 31, 2016
$
2,342,549

 
$
675,380

 
$
408,280

 
$
3,426,209

Accumulated impairment losses as of September 30, 2017 (1)
$
2,342,549

 
$
855,810

 
$
527,614

 
$
3,725,973

__________
(1)
During the nine months ended September 30, 2017, we sold our Litha business. Accordingly, we removed $26.3 million of accumulated impairments from the International Pharmaceuticals segment.
Schedule of other intangible assets
Changes in the amount of other intangible assets for the nine months ended September 30, 2017 are set forth in the table below (in thousands). This table excludes changes related to businesses classified as held for sale, to the extent such changes occurred after the business was classified as held for sale. As such, this table excludes asset impairment charges of $9.6 million related to our Litha business, assets derecognized upon the divestitures of Litha and BELBUCA™ with a combined carrying amount of $26.4 million and net increases resulting from currency translation of $1.5 million related to our Litha and Somar businesses.
Cost basis:
Balance as of December 31, 2016
 
Acquisitions
 
Impairments
(1)
 
Other
(1) (2)
 
Effect of Currency Translation
(1)
 
Balance as of September 30, 2017
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
$
1,123,581

 
$
—

 
$
(222,090
)
 
$
(177,200
)
 
$
209

 
$
724,500

Total indefinite-lived intangibles
$
1,123,581

 
$
—

 
$
(222,090
)
 
$
(177,200
)
 
$
209

 
$
724,500

Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 12 years)
$
465,720

 
$
—

 
$
(8,178
)
 
$
—

 
$
—

 
$
457,542

Tradenames (weighted average life of 12 years)
7,345

 
—

 
(808
)
 
(262
)
 
134

 
6,409

Developed technology (weighted average life of 11 years)
6,223,004

 
—

 
(433,456
)
 
127,037

 
34,893

 
5,951,478

Total finite-lived intangibles (weighted average life of 11 years)
$
6,696,069

 
$
—

 
$
(442,442
)
 
$
126,775

 
$
35,027

 
$
6,415,429

Total other intangibles
$
7,819,650

 
$
—

 
$
(664,532
)
 
$
(50,425
)
 
$
35,236

 
$
7,139,929

 
 
 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2016
 
Amortization
 
Impairments
 
Other
(2)
 
Effect of Currency Translation
 
Balance as of September 30, 2017
Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses
$
(341,600
)
 
$
(21,674
)
 
$
—

 
$
—

 
$
—

 
$
(363,274
)
Tradenames
(6,599
)
 
(42
)
 
—

 
262

 
(30
)
 
(6,409
)
Developed technology
(1,612,154
)
 
(593,774
)
 
—

 
50,163

 
(12,104
)
 
(2,167,869
)
Total other intangibles
$
(1,960,353
)
 
$
(615,490
)
 
$
—

 
$
50,425

 
$
(12,134
)
 
$
(2,537,552
)
Net other intangibles
$
5,859,297

 
 
 
 
 
 
 
 
 
$
4,602,377

__________
(1)
Additional information on the changes in the total gross carrying amount of our other intangible assets is presented below (in thousands):
 
Gross Carrying Amount
December 31, 2016
$
7,819,650

Impairment of certain U.S. Branded Pharmaceuticals intangible assets
(76,196
)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets
(452,623
)
Impairment of certain International Pharmaceuticals intangible assets
(135,713
)
Transfer of intangible assets to Assets held for sale (NOTE 3)
(33,304
)
Removal of fully amortized intangible assets relating to expired or terminated licensing agreements
(17,121
)
Effect of currency translation
35,236

September 30, 2017
$
7,139,929


(2)
Includes reclassification adjustments of $177.2 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the nine months ended September 30, 2017, the removal of fully amortized intangible assets relating to expired or terminated licensing agreements and the transfer of Somar intangible assets to Assets held for sale.
Schedule of changes in gross carrying amount of other intangible assets
Additional information on the changes in the total gross carrying amount of our other intangible assets is presented below (in thousands):
 
Gross Carrying Amount
December 31, 2016
$
7,819,650

Impairment of certain U.S. Branded Pharmaceuticals intangible assets
(76,196
)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets
(452,623
)
Impairment of certain International Pharmaceuticals intangible assets
(135,713
)
Transfer of intangible assets to Assets held for sale (NOTE 3)
(33,304
)
Removal of fully amortized intangible assets relating to expired or terminated licensing agreements
(17,121
)
Effect of currency translation
35,236

September 30, 2017
$
7,139,929
Schedule of future amortization expense
Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2016 is as follows (in thousands):
2017
$
770,341

2018
$
550,784

2019
$
469,602

2020
$
438,638

2021
$
423,931